ArticleAnnals of surgical oncology2022
Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver.
Article in Annals of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Is there a chance for curative treatment for metastatic pancreatic adenocarcinoma? A systematic review with meta-analysis.Langenbeck's archives of surgery · 2025Pooled it
- Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus.ESMO open · 2023Pooled it
- Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study.Journal of gastroenterology · 2026Article
- Vanishing liver metastases in pancreatic cancer: A case report.Oncology letters · 2026Article
- Simultaneous resection of pancreatic cancer and liver metastases following total neoadjuvant therapy: A case series and analysis of the National Cancer Database.Annals of hepato-biliary-pancreatic surgery · 2026Article
- Article
- Liver metastasis surgery followed by radical treatment for pancreatic ductal adenocarcinoma: A case report.Molecular and clinical oncology · 2025Article
- Pancreatic cancer in 2025: Have we found a solution?World journal of gastroenterology · 2025Review
- Pancreatic Cancer with Liver Oligometastases-Different Patterns of Disease Progression May Suggest Benefits of Surgical Resection.Journal of clinical medicine · 2025Article
- Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: A Multicenter National Cohort Study.Journal of hepato-biliary-pancreatic sciences · 2025Article
- Oligometastatic pancreatic cancer: current state of management and emerging therapies.The oncologist · 2025Review
- Is There a Potential Oncologic Role for Local Therapy on Hepatic Metastasis in Patients Who Undergo Curative Pancreatectomy for Pancreatic Cancer?Yonsei medical journal · 2025Article
- The value of preoperative RDW for post-pancreatectomy haemorrhage and surgical prognosis in patients with pancreatic cancer: a retrospective study.BMC cancer · 2025Article
- Review
- Surgical resection for pancreatic ductal adenocarcinoma with liver metastasis: is this the beginning of a new era?Hepatobiliary surgery and nutrition · 2024Article
- Performance of nutritional and inflammatory markers in patients with pancreatic cancer.World journal of clinical oncology · 2024Article
- Unveiling hidden outcomes in malignant gastric outlet obstruction research - insights from a "Pancreas 2000" review.World journal of gastrointestinal endoscopy · 2024Review
- Surgery for Oligometastatic Pancreatic Cancer: Defining Biologic Resectability.Annals of surgical oncology · 2024Review
- Oncological role of surgical resection in patients with pancreatic ductal adenocarcinoma with liver-only synchronous metastases in a single-center retrospective study.Journal of gastrointestinal oncology · 2023Article
- Currently Debated Topics on Surgical Treatment of Pancreatic Ductal Adenocarcinoma: A Narrative Review on Surgical Treatment of Borderline Resectable, Locally Advanced, and Synchronous or Metachronous Oligometastatic Tumor.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundResection of initially oligometastatic pancreatic ductal adenocarcinoma (PDAC) following response to first-line chemotherapy is controversial. We herein updated a previous case series to investigate the oncologic outcomes and preoperative factors that could drive the decision-making process.
methodsThis retrospective analysis was limited to patients with liver-only synchronous metastases who experienced complete regression of the metastatic component and underwent pancreatectomy between October 2008 and July 2020 at two high-volume institutions. Clinical-pathologic variables were captured, and inflammation-based prognostic scores were calculated. Recurrence and survival analyses were performed using standard statistical methods.
resultsOverall, 52 patients were included. FOLFIRINOX was the most employed chemotherapy regimen (63.5%). Post-treatment tumor size, serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA) were significantly decreased relative to baseline evaluation. The median time from diagnosis to pancreatectomy was 10.2 months, while the median time from chemotherapy completion to pancreatectomy was 2 months. Major postoperative complications occurred in 26.9% of patients, while postoperative mortality was nil. The median disease-free survival (DFS) and overall survival (OS) from pancreatectomy were 16.5 and 23.0 months, respectively, and the median OS from diagnosis was 37.2 months. At multivariable analysis, vascular resection, operative time, prognostic nutrition index (PNI) and neutrophil-to-lymphocyte ratio (NLR) were associated with OS. Operative time, platelet × neutrophil/lymphocyte count (SII), and PNI were associated with DFS.
conclusionsWe confirm promising outcomes of selected patients who underwent pancreatectomy following downstaging of liver metastases. The absence of vascular involvement of the primary tumor, good nutritional status, and low inflammatory index scores could be useful to select candidates for resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.